Literature DB >> 2542854

Estrogen and anti-estrogen effects on the growth of human epithelial ovarian cancer in vitro.

J D Nash1, R F Ozols, J F Smyth, T C Hamilton.   

Abstract

An epithelial ovarian cancer cell line, PE04, has been shown to contain high levels of cytosolic estrogen receptor-like binding. Analysis of PE04 cytosol on low-salt sucrose density gradients demonstrated 7-9S binding of [3H]17 beta-estradiol, with specificity consistent with that of an estrogen receptor. When compared with the proliferation of cells grown in monolayer without steroids, a 50% increase in growth rate of the cell line was observed by treatment with 17 beta-estradiol (E2). Growth stimulation was dose-dependent and maximal at 10(-10) M. The E2 effect on substrate-independent growth was more striking; 3 x 10(-9) M produced a 30-fold increase in cloning efficiency. Treatment with 4-hydroxytamoxifen resulted in a dose-dependent inhibition (maximal at 3 x 10(-9) M) of cell growth, which was reversible by E2. Although treatment with estrogen in systems containing functional estrogen receptor commonly results in progesterone receptor synthesis, E2 induction of progesterone receptor could not be demonstrated in this cell line. The endocrine characteristics of PE04 contrast with those of another ovarian cancer cell line, NIH:OVCAR-3, in which E2 induces progesterone receptor but does not stimulate cell proliferation. This is the first report of an ovarian cancer cell line in which the clinically important end-effect of estrogen, cell growth, has been observed. Furthermore, retention of a mitogenic response to estrogen in the apparent absence of progesterone receptor induction has not been described previously in model systems.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2542854     DOI: 10.1097/00006250-198906000-00021

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  10 in total

1.  Hormonal risk factors for ovarian cancer in the Albanian case-control study.

Authors:  Edlira Pajenga; Tefta Rexha; Silva Çeliku; Gazmend Bejtja; Mimoza Pisha
Journal:  Bosn J Basic Med Sci       Date:  2013-05       Impact factor: 3.363

2.  Circulating Estrogens and Postmenopausal Ovarian Cancer Risk in the Women's Health Initiative Observational Study.

Authors:  Britton Trabert; Louise A Brinton; Garnet L Anderson; Ruth M Pfeiffer; Roni T Falk; Howard D Strickler; Sarunas Sliesoraitis; Lewis H Kuller; Margery L Gass; Barbara J Fuhrman; Xia Xu; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-02-05       Impact factor: 4.254

3.  Estrogen stimulation of ovarian surface epithelial cell proliferation.

Authors:  W Bai; B Oliveros-Saunders; Q Wang; M E Acevedo-Duncan; S V Nicosia
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Nov-Dec       Impact factor: 2.416

4.  Reduced PAX2 expression in murine fallopian tube cells enhances estrogen receptor signaling.

Authors:  Jose A Colina; Peter Varughese; Subbulakshmi Karthikeyan; Amrita Salvi; Dimple A Modi; Joanna E Burdette
Journal:  Carcinogenesis       Date:  2020-07-10       Impact factor: 4.944

5.  Is diabetes mellitus a risk factor for ovarian cancer? A case-control study in Utah and Washington (United States).

Authors:  A I Adler; N S Weiss; M L Kamb; J L Lyon
Journal:  Cancer Causes Control       Date:  1996-07       Impact factor: 2.506

6.  Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone.

Authors:  T Yano; J Pinski; S Radulovic; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

Review 7.  Estrogen receptors and human disease.

Authors:  Bonnie J Deroo; Kenneth S Korach
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

8.  Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.

Authors:  T Yano; J Pinski; G Halmos; K Szepeshazi; K Groot; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

9.  GPR30 regulates the EGFR-Akt cascade and predicts lower survival in patients with ovarian cancer.

Authors:  Satoe Fujiwara; Yoshito Terai; Hiroshi Kawaguchi; Masaaki Takai; Saha Yoo; Yoshimichi Tanaka; Tomohito Tanaka; Satoshi Tsunetoh; Hiroshi Sasaki; Masanori Kanemura; Akiko Tanabe; Yoshiki Yamashita; Masahide Ohmichi
Journal:  J Ovarian Res       Date:  2012-11-19       Impact factor: 4.234

Review 10.  Estrogen, progesterone and epithelial ovarian cancer.

Authors:  Shuk-Mei Ho
Journal:  Reprod Biol Endocrinol       Date:  2003-10-07       Impact factor: 5.211

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.